Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
- Conditions
- HypertensionObesityDiabetes MellitusHyperuricemiaChronic Kidney Diseases
- Interventions
- Diagnostic Test: Biomarkers
- Registration Number
- NCT05476627
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- The diagnosis of metabolic diseases were confirmed;
- Be able to understand the process of the research;
- Volunteer for participation and be able to sign the informed consent.
- Age <18 yrs or >80yrs;
- Patients with primary and secondary glomerular diseases
- Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
- Contraindications for MRI examination;
- Pregnant or lactation patients;
- Patients with unstable vital signs, failure of other organs or dysphoria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hypertension Group Biomarkers - Hyperuricemia Biomarkers - Diabetes Group Biomarkers - Obesity Biomarkers -
- Primary Outcome Measures
Name Time Method Number of Participants with End Stage Renal Disease 3 years End Stage Renal Disease
Number of Participants with Adverse cardiovascular events 3 years Adverse cardiovascular events
Number of Participants with all cause death 3 years All cause death
- Secondary Outcome Measures
Name Time Method Number of Participants with eGFR decline 3 years the decline of eGFR during follow-up
Number of Participants with Complications of CKD 3 years The complications of CKD
Life quality assessment with short form-36 (SF-36) 3 years The SF-36 is a patient-reported instrument designed to assess overall health status; it is usually utilized to measure patients' quality of life and used primarily in research. Increasing SF-36 scores are indicative of improving health status.
Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE) 3 years The MMSE is scored on a 30-point scale, with items that assess orientation (temporal and spatial; 10 points), memory (registration and recall; 6 points), attention/concentration (5 points), language (verbal and written; 8 points), and visuospatial function (1 point) . While different cutoff points have been used across studies, scores ≤23 are most commonly regarded as abnormal and indicative of cognitive impairment.
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China